Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Explores Pandemic Inspection Alternatives, Post-Pandemic Strategies

Executive Summary

Agency's Janet Woodcock  and Judy McMeekin say the FDA is looking at options like livestream plant videos while preparing to address backlog after inspections can resume.

You may also be interested in...



ANDA Sponsors Could Lose Exclusivity Because COVID-19 Prevented An Inspection … Or Not

US FDA will determine on a case-by-case basis whether its inability to inspect a facility because of the pandemic could result in 180-day exclusivity forfeiture for first generic filers.

US FDA's On-Time Review Decision Rates Slip During The Pandemic, Especially For Biosimilars

Likelihood of an on-time decision on a biosimilar application dropped significantly during the first nine months of the pandemic and declined a bit for new and generic drug applications. FDA says BsUFA review performance is function of program's small sample size.

US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says

Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel